Search Results - "Teixeira, Henrique D." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

by Simpson, Eric, Bissonnette, Robert, Eichenfield, Lawrence F., Guttman-Yassky, Emma, King, Brett, Silverberg, Jonathan I., Beck, Lisa A., Bieber, Thomas, Reich, Kristian, Kabashima, Kenji, Seyger, Marieke, Siegfried, Elaine, Stingl, Georg, Feldman, Steven R., Menter, Alan, van de Kerkhof, Peter, Yosipovitch, Gil, Paul, Carle, Martel, Philippe, Dubost-Brama, Ariane, Armstrong, John, Chavda, Rajeev, Frey, Steve, Joubert, Yolandi, Milutinovic, Marina, Parneix, Anne, Teixeira, Henrique D., Lin, Chen-Yen, Sun, Luna, Klekotka, Paul, Nickoloff, Brian, Dutronc, Yves, Mallbris, Lotus, Janes, Jonathan M., DeLozier, Amy M., Nunes, Fabio P., Paller, Amy S.
Published in Journal of the American Academy of Dermatology (01.09.2020)

Get full text

Journal Article

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

by Menter, Alan, MD, Thaçi, Diamant, MD, Papp, Kim A., MD, Wu, Jashin J., MD, Bereswill, Mareike, MS, Teixeira, Henrique D., PhD, Rubant, Simone, PhD, Williams, David A., MD
Published in Journal of the American Academy of Dermatology (01.09.2015)

Get full text

Journal Article

Systematic review of efficacy of anti–tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti–TNF agent

Systematic review of efficacy of anti–tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti–TNF agent

by Yamauchi, Paul S., MD, PhD, Bissonnette, Robert, MD, Teixeira, Henrique D., PhD, MBA, Valdecantos, Wendell C., MD
Published in Journal of the American Academy of Dermatology (01.09.2016)

Get full text

Journal Article

Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice

Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice

by Prens, Errol P., Lugo-Somolinos, Aida M., Paller, Amy S., Kerdel, Francisco, Duan, Yinghui, Teixeira, Henrique D., Longcore, Michelle, Kimball, Alexa B.
Published in American journal of clinical dermatology (01.08.2020)

Get full text

Journal Article

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study

by Katoh, Norito, Ohya, Yukihiro, Murota, Hiroyuki, Ikeda, Masanori, Hu, Xiaofei, Ikeda, Kimitoshi, Liu, John, Sasaki, Takuya, Raymundo, Eliza M., Teixeira, Henrique D., Saeki, Hidehisa
Published in Dermatology and therapy (01.01.2023)

Get full text

Journal Article

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis

by Silverberg, Jonathan I., Hong, H. Chih-ho, Calimlim, Brian M., Lee, Wan-Ju, Teixeira, Henrique D., Collins, Eric B., Crowell, Marjorie M., Johnson, Scott J., Armstrong, April W.
Published in Dermatology and therapy (01.10.2023)

Get full text

Journal Article

Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

by Asahina, Akihiko, Ohtsuki, Mamitaro, Etoh, Takafumi, Gu, Yihua, Okun, Martin M., Teixeira, Henrique D., Yamaguchi, Yuji, Nakagawa, Hidemi
Published in Journal of dermatology (01.11.2015)

Get full text

Journal Article

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II

by Kimball, Alexandra B, Tzellos, Thrasivoulos, Calimlim, Brian M, Teixeira, Henrique D, Geng, Ziqian, Okun, Martin M
Published in Acta dermato-venereologica (05.11.2018)

Get full text

Journal Article

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

by Reich, Kristian, Teixeira, Henrique D, de Bruin-Weller, Marjolein, Bieber, Thomas, Soong, Weily, Kabashima, Kenji, Werfel, Thomas, Zeng, Jiewei, Huang, Xiaohong, Hu, Xiaofei, Hendrickson, Barbara A, Ladizinski, Barry, Chu, Alvina D, Silverberg, Jonathan I
Published in The Lancet (British edition) (05.06.2021)

Get full text

Journal Article

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

by Guttman-Yassky, Emma, Teixeira, Henrique D, Simpson, Eric L, Papp, Kim A, Pangan, Aileen L, Blauvelt, Andrew, Thaçi, Diamant, Chu, Chia-Yu, Hong, H Chih-ho, Katoh, Norito, Paller, Amy S, Calimlim, Brian, Gu, Yihua, Hu, Xiaofei, Liu, Meng, Yang, Yang, Liu, John, Tenorio, Allan R, Chu, Alvina D, Irvine, Alan D
Published in The Lancet (British edition) (05.06.2021)

Get full text

Journal Article

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

by Guttman-Yassky, Emma, Thaçi, Diamant, Pangan, Aileen L., Hong, H. Chih-ho, Papp, Kim A., Reich, Kristian, Beck, Lisa A., Mohamed, Mohamed-Eslam F., Othman, Ahmed A., Anderson, Jaclyn K., Gu, Yihua, Teixeira, Henrique D., Silverberg, Jonathan I.
Published in Journal of allergy and clinical immunology (01.03.2020)

Get full text

Journal Article

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

by Blauvelt, Andrew, Teixeira, Henrique D, Simpson, Eric L, Costanzo, Antonio, De Bruin-Weller, Marjolein, Barbarot, Sebastien, Prajapati, Vimal H, Lio, Peter, Hu, Xiaofei, Wu, Tianshuang, Liu, John, Ladizinski, Barry, Chu, Alvina D, Eyerich, Kilian
Published in JAMA dermatology (Chicago, Ill.) (01.09.2021)

Get more information

Journal Article

Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis

Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis

by Ismail, Mohamed, Doelger, Eva, Eckert, Doerthe, Irvine, Alan D, Chu, Alvina D, Teixeira, Henrique D, Liu, Wei, Nader, Ahmed
Published in British journal of clinical pharmacology (01.10.2023)

Get full text

Journal Article

Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS)

Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS)

by Foley, Catherine, Tundia, Namita, Simpson, Eric, Teixeira, Henrique D, Litcher-Kelly, Leighann, Bodhani, Amit
Published in Current medical research and opinion (03.07.2019)

Get more information

Journal Article

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials

by Paller, Amy S, Ladizinski, Barry, Mendes-Bastos, Pedro, Siegfried, Elaine, Soong, Weily, Prajapati, Vimal H, Lio, Peter, Thyssen, Jacob P, Simpson, Eric L, Platt, Andrew M, Raymundo, Eliza M, Liu, Jianzhong, Calimlim, Brian M, Huang, Xiaohong, Gu, Yihua, Hu, Xiaofei, Yang, Yang, Su, John C, Zheng, Min, Yamamoto-Hanada, Kiwako, Teixeira, Henrique D, Irvine, Alan D
Published in JAMA dermatology (Chicago, Ill.) (01.05.2023)

Get more information

Journal Article

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

by Blauvelt, Andrew, Ladizinski, Barry, Prajapati, Vimal H., Laquer, Vivian, Fischer, Alison, Eisman, Samantha, Hu, Xiaofei, Wu, Tianshuang, Calimlim, Brian M., Kaplan, Blair, Liu, Yingyi, Teixeira, Henrique D., Liu, John, Eyerich, Kilian
Published in Journal of the American Academy of Dermatology (01.09.2023)

Get full text

Journal Article

Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis

Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis

by Qian, Yuli, Raymundo, Eliza M., Hao, Shuai, Unnebrink, Kristina, Levy, Gweneth F., Teixeira, Henrique D., Chu, Alvina D., Zinn, Zachary A., Paller, Amy S., Liu, Wei, Mohamed, Mohamed-Eslam F.
Published in Clinical therapeutics (01.10.2024)

Get full text

Journal Article

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks

by Paller, Amy S, Mendes-Bastos, Pedro, Siegfried, Elaine, Eichenfield, Lawrence F, Soong, Weily, Prajapati, Vimal H, Lio, Peter, Simpson, Eric L, Raymundo, Eliza M, Suravaram, Smitha, Hu, Xiaofei, Yang, Yang, Huang, Xiaohong, Calimlim, Brian M, Platt, Andrew M, Su, John C, Zheng, Min, Yamamoto-Hanada, Kiwako, Teixeira, Henrique D, Irvine, Alan D
Published in JAMA dermatology (Chicago, Ill.) (23.10.2024)

Get more information

Journal Article

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

by Mohamed, Mohamed‐Eslam F., Gopalakrishnan, Sathej, Teixeira, Henrique D., Othman, Ahmed A.
Published in Journal of clinical pharmacology (01.05.2021)

Get full text

Journal Article

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

by Katoh, Norito, Ohya, Yukihiro, Murota, Hiroyuki, Ikeda, Masanori, Hu, Xiaofei, Ikeda, Kimitoshi, Liu, John, Sasaki, Takuya, Chu, Alvina D., Teixeira, Henrique D., Saeki, Hidehisa
Published in JAAD international (01.03.2022)

Get full text

Journal Article